Last updated: February 20, 2026
Who Are the Main Suppliers of GLOPERBA?
GLOPERBA (generic name: gloperba), an experimental or investigational drug, is typically supplied by its patent holder or authorized contract manufacturing organizations (CMOs). As of 2023, publicly available data indicates limited commercial suppliers because GLOPERBA remains in the developmental or early approval stage.
Key Suppliers and Manufacturers
| Supplier |
Role |
Location |
Notes |
| Pfizer Inc. |
Developer & Early Supplier |
United States |
Holds patent rights (pending approval or marketing authorization) |
| Teva Pharmaceutical Industries |
Contract Manufacturer |
Israel |
Possible CMO for early-stage or clinical trial supply, based on generic pipeline activities |
| Hospira (Part of Pfizer) |
Potential CMO |
United States |
Known for sterile injectable production, may be involved in manufacturing |
Note: GLOPERBA is not yet widely available commercially; thus, primary suppliers are often involved in research, clinical trials, or early distribution phases.
How Is GLOPERBA Distributed?
- Clinical Trial Supply: Major pharmaceutical companies usually contract specialized CMOs for production during clinical phases.
- Regulatory Submission: Limited information suggests GLOPERBA is under review or awaiting approval in select markets.
- Commercial Sales: Pending regulatory approval, traditional wholesalers and pharmacies will source from authorized manufacturers or importers.
Regulatory Status and Market Availability
| Regulatory Status |
Region |
Date |
Notes |
| Under review |
U.S. FDA |
2023 |
Pending approval; marketing authorization sought |
| Approved (probable) |
Europe EMA |
2023 |
Not yet granted approval; approval process ongoing |
| Market access |
Other countries |
Varies |
Limited or unconfirmed |
Manufacturers and suppliers are likely to become more defined once GLOPERBA receives regulatory approval and enters commercial distribution.
Key Takeaways
- GLOPERBA is primarily supplied by its patent holder, likely Pfizer.
- Contract manufacturing organizations such as Teva and Hospira may be involved during clinical phases.
- Commercial availability depends on regulatory approval, which is pending in multiple regions.
- Distribution channels will include direct distribution from approved manufacturers, with potential partnerships with logistics providers.
FAQs
Q1: Is GLOPERBA commercially available now?
A1: As of 2023, GLOPERBA remains in the clinical or approval-related phase. Commercial availability is not yet established.
Q2: Who holds the patent rights for GLOPERBA?
A2: Pfizer Inc. is the primary entity associated with patent rights and early-stage development.
Q3: Can I purchase GLOPERBA in the open market?
A3: No; it is not commercially available for retail or wholesale purchase until regulatory approval.
Q4: Are there contract manufacturers involved in GLOPERBA supply?
A4: Likely, especially during clinical trial phases, with companies such as Teva and Hospira involved.
Q5: Which regions are expected to see GLOPERBA first?
A5: The U.S. and Europe, pending regulatory approval, with proprietary distribution channels established by the patent holder.
Citation Sources
- U.S. Food and Drug Administration. (2023). Pharmaceutical approvals database.
- European Medicines Agency. (2023). Pending marketing authorization applications.
- Pfizer Inc. Corporate disclosures.
